Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (early Skin Form of Lyme Borreliosis))
- Conditions
- Erythema Migrans of Lyme Disease
- Interventions
- Registration Number
- NCT06451913
- Lead Sponsor
- Biocodex
- Brief Summary
The aim of this study is to assess the effect of Saccharomyces boulardii CNCM I-745 on gut microbiota in patients undergoing antibiotic therapy (in the context of erythema migrans (early skin form of Lyme borreliosis)).
- Detailed Description
The study is designed to compare the efficacy of Saccharomyces boulardii CNCM-I-745 500 mg bid to a placebo in patients undergoing antibiotic therapy in the context of erythema migrans as the early form of Lyme borreliosis.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 120
- Adult Patients, ≥18 years old.
- Who are prescribed antibiotic therapy (as per medical routine practices, amoxicillin 1000 mg bid for 14 days) in the context of erythema migrans (early skin form of Lyme borreliosis).
- Able to comply with study requirements and to provide signed informed consent before any study procedure.
- Has no condition that may interfere with the study assessments.
- Able to fulfil in the diary stool log, according to the physician's opinion.
- Regular defecation (frequency and stool consistency, with at least about three bowel movements a week).
- For women of childbearing potential:
- A negative urine pregnancy test immediately prior to starting the study treatment,
- Agreement to comply with approved methods of contraception during the whole study: unless they meet the criteria of post-menopausal, i.e. 12 months of spontaneous amenorrhea, women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner, should use one or more acceptable methods of contraception that should be maintained throughout the study.
- History of hypersensitivity to the study treatments (active substance or excipients), brewer's or baker's yeast,
- Contraindication and special warning to the study drugs according to the SmPCs,
- History of chronic constipation with passage of fewer than 3 spontaneous bowel movements per week on average,
- History of chronic or recurrent diarrhoea with spontaneous unformed bowel movements equivalent to or more often than 3 times daily,
- Prior gastrointestinal surgery (apart from appendectomy or cholecystectomy performed at least more than one year ago),
- History of Clostridium difficile infection,
- Active gastrointestinal inflammatory disease,
- Known chronic or recurrent systemic disorder that may interfere with the study drug evaluation,
- Immunocompromised (organtransplants, leukaemia, malignant tumours, radiotherapy, chemotherapy,prolonged high dose cortisone treatment, immunosuppressant treament) or critically ill patients (such as autoimmune disease, HIV,...), patients with a central venous catheter,
- Severe hepatic or renal impairment,
- Systemic antibacterial therapy during the 2 months prior to study enrollment,
- New prescription medications during the 2 weeks prior to study enrollment,
- Use of any drug or product that alters gut microbiota or function, such as probiotics, laxatives, antiemetics, cisapride, antisecretory or adsorbent treatments (racecadotril, smectite, activated charcoal), opiates such as loperamide, atropine and other cholinergic agents, 4 weeks prior to study enrollment and during the study,
- Intake of antifungals within 14 days prior to study enrollment,
- Substantial changes in eating habits within 30 days prior to receiving the first dose of IMP product, and during the study as assessed by the Investigator,
- History or presence of drug or alcohol abuse,
- Heavy smoker (more than 10 cigarettes per day),
- Breast-feeding woman,
- Patients enrolled in another interventional clinical trial where they received an investigation treatment within the past 30 days,
- Any condition or personal circumstance that, in the opinion of the investigator, rendered the subject unlikely or unable to comply with the full study protocol
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Amoxicillin + Saccharomyces boulardii CNCM I-745 Amoxicillin + Saccharomyces boulardii CNCM I-745 The patients will received oral Amoxicillin (1000 mg capsules bid) for 14 days and oral Saccharomyces boulardii CNCM I-745 (®) 250 mg x 2 capsules twice a day for 21 days. Amoxicillin + Saccharomyces boulardii CNCM I-745 Stool samples The patients will received oral Amoxicillin (1000 mg capsules bid) for 14 days and oral Saccharomyces boulardii CNCM I-745 (®) 250 mg x 2 capsules twice a day for 21 days. Amoxicillin + Placebo Amoxicillin + Placebo The patients will received oral Amoxicillin (1000 mg capsules bid) for 14 days + oral Placebo capsules for 21 days. Amoxicillin + Placebo Stool samples The patients will received oral Amoxicillin (1000 mg capsules bid) for 14 days + oral Placebo capsules for 21 days.
- Primary Outcome Measures
Name Time Method Assessment of the effect of Saccharomyces boulardii CNCM I-745, an antibiotic, and their combination on the gut microbiota of patients receiving antibiotic At Day 1, Day 7, Day 14 and Day 21 Primary endpoint : analysis of the intestinal microbiota in the patient's stools
- Secondary Outcome Measures
Name Time Method Assessment of the efficacy of Saccharomyces boulardii CNCM I-745 on the stools in patients undergoing antibiotic therapy : Recorded stools in the Bristol Stool Form Scale (BSFS) At Day 1, Day 7, Day 14 and Day 21 Secondary efficacy endpoint : Time frame in hours up to the time of the last liquid or loose stool (defined as types 6 or 7 on Bristol Stool Form Scale (BSFS)) followed by the first 24-hour period with stool consistency improvement (no liquid or loose stool), as recorded by the patients in the stool diary or as collected by the investigator
Assessment of the efficacy of Saccharomyces boulardii CNCM I-745 in prevention of antibiotic-associated diarrhoea (AAD) in patients undergoing antibiotic therapy At Day 1, Day 7, Day 14 and Day 21 Secondary efficacy endpoint : Incidence of AAD (The number of AAD episodes that occurred during the treatment period) will be assessed using the Bristol Stool Form Scale (BSFS) recorded daily.
Assess the effect of Saccharomyces boulardii CNCM I-745, an antibiotic, and their combination on the gastro-intestinal symptoms of patients receiving antibiotic therapy : Changes from baseline of the GSRS Weekly from Day 1 to Day 21 Secondary efficacy endpoint : Changes from baseline of the Gastrointestinal Symptom Rating Scale (GSRS) score (total score) and diarrhea sub-scores will be compared weekly between the treatment groups. The questionnaire, which contains 15 items, uses a seven-graded Likert scale, where 1 represents the most positive option and 7 the most negative one.